Poster Oral Presentation 2

[PO-016] Integrated Long-Term Safety of Ozanimod From Clinical Trials Across 2 Different Indications

*Hiroshi Nakase¹, David T. Rubin², Silvio Danese³, Peter Irving⁴, Douglas C. Wolf⁵, Preetika Sinh⁶, Bruce A. C. Cree⁷, Olga Alekseeva⁸, Fred D. Lublin⁹, Norma Ruiz Santiago¹⁰, Zhaohui Liu¹⁰, AnnKatrin Petersen¹⁰, Dimpy Mehra¹⁰, Anjali Jain¹⁰, Anthony Krakovich¹⁰, Chun-Yen Cheng¹⁰, Jon V. Riolo¹⁰, Erik DeBoer¹⁰, Jeffrey A. Cohen¹¹, Ryan C. Ungaro⁹ (1. Sapporo Medical University, Sapporo, Japan, 2. University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA, 3. Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy, 4. Guy’s and St Thomas’ NHS Foundation Trust, London, UK, 5. Center for Crohn’s Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, GA, USA, 6. Division of Gastroenterology, Medical College of Wisconsin, Milwaukee, WI, USA, 7. Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA, 8. Department of Gastroenterology, Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russia, 9. Icahn School of Medicine at Mount Sinai, New York, NY, USA, 10. Bristol Myers Squibb, Princeton, NJ, USA, 11. Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.